TETRA Technologies, Inc. logo TTI - TETRA Technologies, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 18
HOLD 13
SELL 0
STRONG
SELL 0
| PRICE TARGET: $12.25 DETAILS
HIGH: $13.00
LOW: $11.50
MEDIAN: $12.25
CONSENSUS: $12.25
UPSIDE: 17.68%

Stock News

Thiogenesis Announces Non-Brokered Private Placement

Thiogenesis Announces Non-Brokered Private Placement

San Diego, California--(Newsfile Corp. - May 11, 2026) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing a next-generation cysteamine-based therapy for rare diseases, announced today that it will undertake a non-brokered private placement (the "Offering") of up to 16,000,000 common shares of the Company ("Offered Shares") at a price of $0.50 per Common Share for gross proceeds of $8 million. This Offering is subject to the approval of the TSX Venture Exchange (the "Exchange").

May 11, 2026 05:00 AM • newsfilecorp.com
TETRA Technologies: Deep In The Oil Patch, A Critical Minerals Play Is Taking Shape

TETRA Technologies: Deep In The Oil Patch, A Critical Minerals Play Is Taking Shape

TETRA Technologies reported decade-high Q1 2026 revenue and EBITDA, with EPS coming 100% above estimates despite flat year-over-year growth. The company is constructing an Arkansas bromine facility for zinc bromide electrolyte battery supply. This is the project that contributes to the growth of the company in the near future. At 14x EV/EBITDA, TTI trades at the same multiple as Generac, although TTI holds bromine supply chain exposure and dominant deepwater completion fluid market share.

May 10, 2026 10:20 PM • seekingalpha.com
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update

Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update

Topline results from healthy volunteer study and clinical development strategy  for next-generation STAT3 inhibitor, TTI-109, anticipated in June Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) on track for 2H 2026 Cash runway expected to be sufficient to fund operations through clinical readouts  and into Q4 2026 HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its financial and operating results for the first quarter ended March 31, 2026, and provided a business update. Recent Progress and Upcoming Catalysts: TTI-109 (Healthy Volunteer Study): Study ongoing with topline data anticipated in June 2026.

May 08, 2026 03:00 AM • globenewswire.com
TETRA TECHNOLOGIES, INC. REPORTS STRONG FIRST-QUARTER 2026 RESULTS MAINTAINS 2026 GUIDANCE

TETRA TECHNOLOGIES, INC. REPORTS STRONG FIRST-QUARTER 2026 RESULTS MAINTAINS 2026 GUIDANCE

SPRING, Texas, April 29, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE:TTI) announced financial results for the three months ended March 31, 2026. First-Quarter 2026 Financial Highlights Revenues of $156.3 million Income from continuing operations of $8.3 million, inclusive of $0.5 million of unusual charges Adjusted EBITDA of $25.6 million Income per share from continuing operations of $0.06 Brady Murphy, TETRA's President and Chief Executive Officer, stated, "We are pleased to start 2026 with one of the strongest first quarter performances in the company's past ten years.

Apr 29, 2026 01:00 PM • prnewswire.com
Thiogenesis Therapeutics to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference

Thiogenesis Therapeutics to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference

San Diego, California--(Newsfile Corp. - April 16, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing sulfur-based prodrugs designed as precursors to thiol-active compounds such as cysteamine, today announced that management will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference, taking place in Toronto, Canada. Presentation Details: Date: Wednesday, April 22, 2026Time: 1:30-2:00 p.m.

Apr 16, 2026 05:00 AM • newsfilecorp.com
Allspring Global Investments Holdings LLC Makes New $7.39 Million Investment in Tetra Technologies, Inc. $TTI

Allspring Global Investments Holdings LLC Makes New $7.39 Million Investment in Tetra Technologies, Inc. $TTI

Allspring Global Investments Holdings LLC acquired a new position in shares of Tetra Technologies, Inc. (NYSE: TTI) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 788,253 shares of the oil and gas company's stock, valued at approximately $7,386,000. Allspring Global Investments Holdings LLC owned 0.59%

Apr 06, 2026 11:13 PM • defenseworld.net
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update

Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update

Results from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 2026 Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) are anticipated in H2 2026 Cash runway expected to be sufficient to fund operations into Q4 2026 after clinical readouts HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced its financial and operating results for the fourth quarter and full-year ended December 31, 2025, and provided a business update. Recent Highlights: Additional analysis from the REVERT IPF Phase 2 trial demonstrated that TTI-101 was associated with a 9.4% baseline-weighted reduction in fibrosis score compared to 2.4% for placebo, as well as a 4.5-fold greater decline in IL-6, a central STAT3-driven inflammatory cytokine.

Mar 31, 2026 12:01 PM • globenewswire.com
Critical Review: Tetra Technologies (NYSE:TTI) versus Subsea 7 (OTCMKTS:SUBCY)

Critical Review: Tetra Technologies (NYSE:TTI) versus Subsea 7 (OTCMKTS:SUBCY)

Subsea 7 (OTCMKTS:SUBCY - Get Free Report) and Tetra Technologies (NYSE: TTI - Get Free Report) are both energy companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings. Institutional and Insider Ownership 0.0% of Subsea 7

Mar 27, 2026 10:30 PM • defenseworld.net
TETRA TECHNOLOGIES, INC. TO PARTICIPATE IN THE PIPER SANDLER 26TH ANNUAL ENERGY CONFERENCE

TETRA TECHNOLOGIES, INC. TO PARTICIPATE IN THE PIPER SANDLER 26TH ANNUAL ENERGY CONFERENCE

SPRING, Texas, March 4, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE:TTI) announced that Brady Murphy, Chief Executive Officer; Elijio Serrano, Chief Financial Officer; and Kurt Hallead, VP of Investor Relations and Treasurer, will be hosting one-on-one meetings with institutional investors on March 17, 2026 during the Piper Sandler 26th Annual Energy Conference in Las Vegas. Investors interested in scheduling one-on-ones meetings at the conference should contact their Piper Sandler sales representative.

Mar 04, 2026 10:02 AM • prnewswire.com
TETRA TECHNOLOGIES, INC. ANNOUNCES FOURTH-QUARTER AND STRONG FULL-YEAR 2025 RESULTS AND PROVIDES UPDATE ON STRATEGIC INITIATIVES

TETRA TECHNOLOGIES, INC. ANNOUNCES FOURTH-QUARTER AND STRONG FULL-YEAR 2025 RESULTS AND PROVIDES UPDATE ON STRATEGIC INITIATIVES

SPRING, Texas, Feb. 25, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE:TTI) announced financial results for the three and twelve months ended December 31, 2025. Fourth-Quarter 2025 Financial Highlights Revenues of $146.7 million increased 9% from the fourth quarter of 2024 Loss from continuing operations was $15.3 million, inclusive of $18.7 million of unusual charges Loss per share from continuing operations was $0.11 while Adjusted net income per share was $0.02, excluding unusual charges Adjusted EBITDA was $20.4 million Net cash provided by operating activities was $31.7 million - materially above the prior sequential quarter and the fourth quarter of 2024; Adjusted free cash flow was $3.1 million and base business adjusted free cash flow was exceptionally strong at $21.8 million.

Feb 25, 2026 12:07 PM • prnewswire.com
Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update

Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update

San Diego, California--(Newsfile Corp. - February 2, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare pediatric diseases, today provided an update on its nephropathic cystinosis program and announced a new investigator-initiated study (IIS) collaboration with Dr. Larry Greenbaum, a recognized global leader in cystinosis research, at Emory University and Children's Healthcare of Atlanta. The IIS will evaluate Thiogenesis' lead product candidate, TTI-0102, a next-generation cysteamine-based prodrug, in patients with nephropathic cystinosis to further characterize once-daily dosing, tolerability, and white blood cell (WBC) cystine control across a representative patient population.

Feb 02, 2026 04:00 AM • newsfilecorp.com

Price Targets